EC 1169

Drug Profile

EC 1169

Alternative Names: DUPA-TubH III; EC 1719; EC-1069; EC1169; PSMA-Tubulysin

Latest Information Update: 17 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Biological toxins; Drug conjugates; Peptides; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase-I trial in Prostate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 Mar 2017 Endocyte initiates enrolment in a phase I trial for Prostate cancer (late-stage disease, recurrent, second-line therapy or greater) in USA (IV) (NCT02202447)
  • 10 Oct 2016 Efficacy and adverse events data from a phase I trial in Prostate cancer presented at the European Society for Medical Oncology (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top